Background: Measured endocrinological parameters (total testosterone [TT], free testosterone [FT], dihydrotestosterone [DHT], dehydroepiandrosterone sulfate [DHEAS], and sex hormone binding globulin [SHBG]) and calculated parameters (calculated FT (cFT), calculated bioavailable testosterone (cBT), and the free androgen index [FAI]) in women with hirsutism were compared to the values of a control group. The question remains if cFT or cBT are more appropriate markers for assessment of hyperandrogenemia in clinical situations such as hirsutism in women. Methods: Sixty-six women showed an modified Ferriman-Gallwey (mF-G) score of ≧6 and were classified as hirsutism group and 58 women showed mF-G scores of ≤5 and were classified as control group. TT, FT, DHT, DHEAS, and SHBG were measured with enzyme immunoassays in one serum sample. Albumin was measured in the same sample. Afterwards, cFT, cBT, and the FAI were calculated. Results: The hirsutism group revealed significantly increased cFT, cBT, and FAI, while SHBG was significantly decreased compared to the controls. All values of the hirsutism group showed significant, but poor correlation with the mF-G score. SHBG correlated negatively with the mF-G score and BMI. Conclusion: Despite the limited correlation of all endocrinological parameters to severity of hirsutism described by the mF-G score, cFT, cBT, and FAI may be more appropriate markers for assessment of hyperandrogenemia in women with hirsutism in comparison with measured values of simple enzyme immunoassays.

1.
Souter I, Sanchez LA, Perez M, Bartolucci AA, Azziz R: The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstet Gynecol 2004;191:1914–1920.
2.
Ferriman D, Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440–1447.
3.
Vermeulen A, Verdonck L, Kaufmann JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666–3672.
4.
Vermeulen A, Stoica T, Verdonck L: The apparent free testosterone concentration, an index of androgenicity. J Clin Endocrinol 1971;33:757–767.
5.
McCann DS, Kirkish LS: Evaluation of free testosterone in serum. J Clin Immunoassay 1985;8:234–236.
6.
Hammond GL, Nisker JA, Jones LA, Siiteri PK: Estimation of the percentage of free steroid in undiluted serum by centrifugal ultrafiltration-dialysis. J Biol Chem 1980;255:5023–5026.
7.
Vlahos I, Macmahon W, Sgoutas D, Bowers W, Thompson J, Trawick W: An improved ultrafiltration method for determining free testosterone in serum. Clin Chem 1982;28:2286–2291.
8.
Ooi DS, Innanen VT, Wang D, Chong Gl, Donnelly JG, Arseneult JJ, Pronovost C, Wells G: Establishing reference intervals for DPC’s free testosterone radioimmunoassay. Clin Biochem 1998;31:15–21.
9.
Wilke TJ, Utley DJ: Total testosterone, free androgen index, calculated free testosterone and free testosterone by analog RIA compared in hirsute women and in otherwise normal women with altered binding of sex hormone binding globulin. Clin Chem 1987;33:1372–1375.
10.
Rosner W: Errors in the measurement of plasma free testosterone. J Clin Endocrinol Metab 1997;82:2014–2015.
11.
Sodergard R, Backstrom T, Shanbhag V, Carstensen H: Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801–810.
12.
Mathur RS, Moody LO, Landgrebbe S, Williamson HO: Plasma androgens and sex hormone binding globulin in the evaluation of hirsute patients. Fertil Steril 1981;35:29–37.
13.
Tsujimura A, Matsumiya K, Miyagawa Y, Takao T, Fujita K, Takada S, Koga M, Iwasa A, Takeyama M, Okuyama A: Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis. Int J Impot Res 1981;23:1–5.
14.
Hatch R, Rosenfield RL, Moon HK, Tredway D: Hirsutism: implications, etiology and management. Am J Obstet Gynecol 1981;140:815–830.
15.
Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group: Revised 2003 consensus on diagnostic criteria and long term health risk related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:1–7.
16.
Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR: Androgen excess in women: experience with over 1,000 consecutive patients. J Clin Endocrinol Metab 2004;89:453–462.
17.
Archer JS, Chang RJ: Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynecol 2004;18:737–754.
18.
Azziz R: The evaluation and management of hirsutism. Obstet Gynecol 2003;101:995–1007.
19.
Falsetti L, Gambera A, Andrico S, Sartori E: Acne and hirsutism in polycystic ovary syndrome: clinical, endocrine-metabolic and ultrasonographic differences. Gynecol Endocrinol 2002;16:275–284.
20.
Thiboutot D, Chen WC: Update and future of hormonal therapy in acne. Dermatology 2003;206:57–67.
21.
Ly PL, Handelsman DJ: Empirical estimation of free testosterone from testosterone and sex hormone-binding globulin immunoassays. Eur J Endocrinol 2005;152:471–478.
22.
Van Uytfanghe K, Stöckle D, Kaufman JM, Fiers T, De Leenheer A, Thienpont LM: Validation of 5 routine assays for serum free testosterone with a candidate reference measurement procedure based on ultrafiltration and isotope dilution-gas chromatography-mass spectrometry. Clin Biochem 2005;38:253–261.
23.
Emadi-Konjin P, Bain J, Bromberg IL: Evaluation of an algorithm for calculation of serum ‘bioavailable’ testosterone (BAT). Clin Biochem 2003;36:591–596.
24.
Borgia F, Cannavo S, Guarneri F, Vannavo SP, Vaccaro M, Guarneri B: Correlation between endocrinological parameters and acne severity in adult women. Acta Dermatol Venerol 2004;84:201–204.
25.
Oren I, Fleishman SJ, Kessel A, Ben-Tal N: Free diffusion of steroid hormones across biomembranes: a simplex search with implicit solvent model calculations. Biophys J 2004;87:768–779.
26.
Zouboulis CC, Degitz K: Androgen action on human skin – from basic research to clinical significance. Exp Dermatol 2004;13:5–10.
27.
Elmlinger MW, Kuhnel W, Wormstall H, Doller PC: Reference intervals for testosterone, androstenedione and SHBG levels in healthy females and males from birth until old age. Clin Lab 2005;51:625–632.
28.
Yucel A, Noyan V, Sagsoz N: The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol DOI:10.1016/j.ejogrb.2005.11.012.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.